AVXL (32) OTLK (38) HUMA (31) MOLN (50) ⌘ Pro Terminal →

Armata Pharmaceuticals Inc. (ARMP) — RQD Stock Rating Cockpit

$3.28 +0.92% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.28

Armata Pharmaceuticals Inc. (ARMP) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $120.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ARMP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ARMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Armata Pharmaceuticals Inc. (NYSE: ARMP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $3.28 (+0.92% 1D, market cap $120.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ARMP ranks #462 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ARMP compare to AVXL and OTLK in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARMP carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AVXL (Anavex Life Sciences Corp.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $120.5M) and OTLK (Outlook Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $120.1M). Among the 5-stock peer group, ARMP leads on earnings multiple (N/A) while ARMP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ARMP?

▼

Per ARMP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000921114), Armata Pharmaceuticals Inc. generated $0 in revenue, -$173.8M in net income, and -$26.3M in free cash flow against $76.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.28 (-0.02%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARMP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY ARMP SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (28% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 43.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$3.63-7.2% Next Q

Q2 (-2Q)

Grade D$3.37+8% Next Q

Q3 (-1Q)

Grade D$3.64-9.9% Next Q

Current

Grade D-$3.28-6.7% Hist 90D α

Trajectory: C- (51) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ARMP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ARMP currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.18) and Max Pain ($3.44) forces dealer call-delta covering toward $15.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARMP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ARMP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

43.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $3$3.28H: $15

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ARMP

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (45)

-35.0% ROIC with 42.0% gross margin and -21.77% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (40)

12/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like ARMP

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARMP)

✓Walkthrough of ARMP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ARMP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -67.13%📐 HORIZONTAL RANGE

2026-10-30O $3.39H $3.44L $3.20C $3.28VOL 46.7K

RES: $7.72SUP: $2.42SMA50: $4.18SMA200: $7.01

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ARMP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ARMP Butterfly Map → + Track ARMP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ARMP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ARMP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ARMP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARMP)

Health Care Rank #462 of 1016 ⚔️ AVXL vs ARMP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ARMP vs. AVXL, OTLK, HUMA, MOLN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Armata Pharmaceuticals Inc. (ARMP) ranks #462 by composite RQD confidence (43/100, grade D-) and #633 by equity capitalization ($120.8M). Within this direct 5-issuer industry benchmark cohort, ARMP leads on earnings valuation at N/A trailing P/E, while ARMP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MOLN currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with ARMP at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ARMP ACTIVE Armata Pharmaceuticals Inc.	D-	43/100	—	—	-35.0%	+0.92%	$120.8M	Benchmark Subject
AVXL Anavex Life Sciences Corp.	E	32/100	—	—	-35.0%	-8.46%	$120.5M	/avxl-vs-armp →
OTLK Outlook Therapeutics Inc.	D-	38/100	—	4.0%	-35.0%	-5.15%	$120.1M	/otlk-vs-armp →
HUMA Humacyte Inc.	E	31/100	—	-30.0%	-35.0%	-12.47%	$130.5M	/huma-vs-armp →
MOLN Molecular Partners AG	D	50/100	—	—	—	+1.42%	$132.4M	/moln-vs-armp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000921114

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Armata Pharmaceuticals Inc. (ARMP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$173.8M, operating cash flow of -$25.8M, and free cash flow of -$26.3M (+33.3% YoY). On the balance sheet, ARMP closed FY2025 with $76.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$173.8M	-$25.8M	-$26.3M	$76.9M	—
FY2024 (FY)	2024-12-31	$0	-$18.9M	-$37.6M	-$39.4M	$86.4M	—
FY2023 (FY)	2023-12-31	$0	-$69.0M	-$47.4M	-$47.4M	—	—

3. ARMP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ARMP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ARMP compare to AVXL and OTLK in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ARMP?

Where is ARMP trading relative to its 50-day, 200-day, and 52-week technical levels?

ARMP last traded at $3.28 (+0.92% on volume of 46,747 shares), positioning the stock -21.53% below its 50-day simple moving average ($4.18) and -53.21% below its 200-day simple moving average ($7.01). Across its 52-week range of $2.75 to $14.98, ARMP sits at the 4.3% percentile with a 14-day RSI of 43.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.87 to $3.69).

ARMP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ARMP stock right now?

Armata Pharmaceuticals Inc. (ARMP) currently earns a Roarable Rating of D- (Sell — SELL) with 43/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is ARMP's 12-month price target and RQD AI Jury consensus?

ARMP's 12-month base price target is $3.06 (range $2.39 to $15.73), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ARMP RQD Cockpit ARMP 12M Forecast ARMP Earnings & Move ARMP Dividends & DRIP ARMP Insiders & 13F ARMP Whale Options ARMP Profit Sankey ARMP News & Why

ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ARMP — Armata Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:43:23Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ARMP scores 43 out of 100 and receives a D- grade, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 9/20 (ROIC -35%; FCF yield -21.77%), indicating the business is consuming rather than generating cash on a return basis. Whale 13F Flow scores 9/20 (institutional accumulation and options positioning), a weak signal. Insider Conviction scores 3/20 (SEC Form 4 and Congressional PTR cluster flow), the lowest pillar and a signal of limited insider confidence per the rating. Macro Regime Fit scores 12/20 (Beta 1.0; sector sensitivity), a moderate reading with market-level volatility exposure. Forensic Balance Sheet scores 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), reflecting a middling but weak financial-health profile.

For a prospective investor evaluating the stock today, the pillar pattern implies that upside depends on a turnaround in cash generation that the source data does not show; negative ROIC and FCF yield mean valuation cannot be anchored to current earnings power. The lowest scores in insider conviction and institutional flow mean there is limited evidence of informed-capital support. Valuation tradeoffs are asymmetric: a low market capitalization ($120.8M) combined with a wide 52-week range ($2.75 - $14.98) reflects high volatility, and the current price of 3.28 sits near the lower end of that range. Second-order risk includes dilution or financing needs, which the source data does not quantify.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the headlines are predominantly market-wire and data-aggregator items referencing ARMP, all marked YELLOW. The most substantive catalyst is a PR Newswire item reporting that the company strengthened its intellectual property portfolio with two recent U.S. patent issuances. Other items (Stocktwits, Yahoo Finance UK, TradingView, and related seasonal-chart pages) are general market coverage without specific fundamental detail. Risk watch items include the absence of revenue and the cash decline noted in the financials. The Butterfly Supply-Chain Graph reports no supply chain and no proprietary signals.

Open Questions

What is the company's cash runway given $8.7M in cash against FY 2025 FCF of $-26.3M, and what financing is planned?
What explains the FY 2025 net loss of $-173.8M when operating loss was $-36.6M, and is there a non-operating or one-time component?
What commercial or clinical milestones underpin the company's valuation absent reported revenue?
What are the terms and remaining life of the recently issued U.S. patents referenced in the news feed?
What is the company's debt position, given the source data reports debt as N/A while Debt/Equity is 0.5?

ARMP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Armata Pharmaceuticals Inc. (ARMP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ARMP Debate Forum (3) ↓

🟡 MARKET WIRE Stocktwits • 7h ago

ARMP: Armata Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 10h ago

Armata Pharmaceuticals, Inc. (ARMP) Seasonal returns chart

Yahoo Finance UK report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 13h ago

Armata Pharmaceuticals, Inc. Estimates – AMEX:ARMP

TradingView report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE PR Newswire • 16h ago

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

PR Newswire report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 19h ago

iNtRON Biotechnology, Inc. (048530.KQ) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago

Innoviva, Inc. (INVA) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

COSCIENS Biopharma Inc. (CSCIF) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Hyloris Pharmaceuticals SA (HYL.BR) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Armata Pharmaceuticals Inc. (ARMP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ARMP Bull vs. Bear Conversation Board — What's Your Call at $3.28?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ARMP 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.89 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ARMP (D- • RQD 43/100) a Buy at $3.28?

Welcome to the ARMP (Armata Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 43/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.62 (-20.1%)

Spot @ $3.28

Pump the brakes on ARMP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ARMP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Armata Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.20 (+28.0%)

Spot @ $3.28

ARMP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ARMP, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $3.28 (52-wk range $2.75 - $14.98), any beat on forward guidance forces shorts and underweight funds to chase.